Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05819528 Not yet recruiting - Clinical trials for Primary Cardiac Lymphoma

Primary Cardiac Lymphoma: Italian Multicenter Experience

Start date: September 1, 2023
Phase:
Study type: Observational

The rationale of this study is to provide an overview on PCL (Primary Cardiac Lymphoma) in Italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be helpful in clinical practice.

NCT ID: NCT05816850 Recruiting - Follicular Lymphoma Clinical Trials

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

FIL_FOLL-BIO
Start date: September 19, 2023
Phase:
Study type: Observational

This is a Multicenter, Retrospective, Biological study ancillary to FOLL12 trial to evaluate the role of EZH2 aberrations in patient with FL treated with immunochemotherapy. Moreover, several novel biomarkers of FL will be investigated.

NCT ID: NCT05816746 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Decitabine and Anti-PD-1 in R/R DLBCL

Start date: May 15, 2023
Phase: Phase 2
Study type: Interventional

Patients with relapsed/refractory diffuse large B cell lymphoma with extranodal (esp. central nervous system) involvement treated with Low-Dose Decitabine plus anti-PD-1 regimen. 3 weeks for a cycle, with a total of 2 years or until the disease progress esor unacceptable toxicity occurs, or the patient decides to withdraw from the trial.

NCT ID: NCT05814848 Not yet recruiting - Clinical trials for Relapsed or Refractory B-cell Lymphoma

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Start date: June 20, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of post-marketing Regiorense injection secondary infusion in the treatment of adult patients with relapsed or refractory B-cell lymphoma.

NCT ID: NCT05813132 Completed - Lymphoma Clinical Trials

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The proposed research aims to compare between BeEAM standard regimen and CEM as conditioning regimen in lymphoma patients in safety profile& toxicity, infections (Febrile neutropenia) during transplant, time to engraftment (recovery not neutropenic), Length of stay at hospital, time to relapse, and other complications.

NCT ID: NCT05806580 Recruiting - Clinical trials for Relapsed or Refractory B-cell Lymphoma

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Start date: May 1, 2022
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of post-marketing Regiorense injection secondary infusion in the treatment of adult patients with relapsed or refractory B-cell lymphoma.

NCT ID: NCT05806099 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

Start date: June 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose escalation part (Phase I) and an expansion part (Phase Ⅱ)

NCT ID: NCT05805943 Recruiting - Clinical trials for CD20-positive B-cell Non-Hodgkin's Lymphoma

Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Start date: March 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of IMM0306 in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL).

NCT ID: NCT05805605 Recruiting - Clinical trials for Myelodysplastic Syndromes

Allo HSCT Using RIC and PTCy for Hematological Diseases

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.

NCT ID: NCT05803395 Recruiting - COVID-19 Clinical Trials

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Start date: September 12, 2023
Phase:
Study type: Observational

This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who received first COVID-19 prophylaxis dose between March 2022 and October 2022.